Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer (Q35354010)

7 August 2017

title

Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer (English)

1 reference

evasion of host immune response

7 August 2017

1 reference

1 reference

1 reference

Bennett MW

1

1 reference

7 August 2017

O'connell J

2

1 reference

7 August 2017

O'sullivan GC

3

1 reference

7 August 2017

Roche D

4

1 reference

7 August 2017

Brady C

5

1 reference

7 August 2017

Kelly J

6

1 reference

7 August 2017

Collins JK

7

1 reference

7 August 2017

Shanahan F

8

1 reference

7 August 2017

language of work or name

English

0 references

publication date

1 February 1999

1 reference

7 August 2017

1 reference

7 August 2017

volume

44

1 reference

7 August 2017

issue

2

1 reference

7 August 2017

page(s)

156-162

1 reference

Gene transfer of Fas ligand induces tumor regression in vivo

7 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1727385

Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1727385

Inhibition of the alloantibody response by CD95 ligand

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1727385

Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1727385

The Fas counterattack: a molecular mechanism of tumor immune privilege

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1727385

Expression of Fas ligand in liver metastases of human colonic adenocarcinomas

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1727385

Lymph node metastasis and relation to tumor growth potential and local immune response in advanced gastric cancer.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1727385

Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1727385

Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1727385

Human lung carcinomas express Fas ligand.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1727385

The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1727385

CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1727385

Cotransplantation of allogeneic islets with allogeneic testicular cell aggregates allows long-term graft survival without systemic immunosuppression

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1727385

Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1727385

Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1727385

Expression of the functional soluble form of human fas ligand in activated lymphocytes.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1727385

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1727385

Fas ligand mediates activation-induced cell death in human T lymphocytes

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1727385

Apoptosis defects analyzed in TcR transgenic and fas transgenic lpr mice

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1727385

Activation induces sensitivity toward APO-1 (CD95)-mediated apoptosis in human B cells.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1727385

Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1727385

The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1727385

Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege

26 September 2018

1 reference

12 December 2020

The expression of tumor-rejection antigen "MAGE" genes in human gastric carcinoma

1 reference

12 December 2020

A role for CD95 ligand in preventing graft rejection

1 reference

12 December 2020

Fc receptor-induced expression of Fas ligand on activated NK cells facilitates cell-mediated cytotoxicity and subsequent autocrine NK cell apoptosis

1 reference

12 December 2020

Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice

1 reference

12 December 2020

Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape

1 reference

12 December 2020

Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion?

1 reference

12 December 2020

Antitumor effect of locally produced CD95 ligand

1 reference

12 December 2020

HLA class-I-restricted and tumor-specific CTL in tumor-infiltrating lymphocytes of patients with gastric cancer

1 reference

12 December 2020

Fas ligand is positioned in mouse uterus and placenta to prevent trafficking of activated leukocytes between the mother and the conceptus

1 reference

12 December 2020

FasL--too much of a good thing? Transplanted grafts of pancreatic islet cells engineered to express Fas ligand are destroyed not protected by the immune system

1 reference

12 December 2020

Identifiers

DOI

10.1136/GUT.44.2.156

1 reference

7 August 2017

1 reference

7 August 2017

1 reference